Sodium-glucose cotransporter (SGLT)-2-inhibitorer til patienter med type 2-diabetes
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Sodium-glucose cotransporter (SGLT)-2-inhibitorer til patienter med type 2-diabetes. / Røder, Michael Einar; Storgaard, Heidi; Rungby, Jørgen; Knop, Filip Krag; Vilsbøll, Tina.
In: Ugeskrift for Laeger, Vol. 178, No. 26, V05160310, 26.12.2016, p. 2461-64.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Sodium-glucose cotransporter (SGLT)-2-inhibitorer til patienter med type 2-diabetes
AU - Røder, Michael Einar
AU - Storgaard, Heidi
AU - Rungby, Jørgen
AU - Knop, Filip Krag
AU - Vilsbøll, Tina
PY - 2016/12/26
Y1 - 2016/12/26
N2 - The sodium-glucose cotransporter 2 inhibitor (SGLT-2i)-class is efficacious as monotherapy and as add-on therapy with an expected lowering of the glycated haemoglobin (HbA1c) concentration of approximately 7 mmol/mol. Side effects relate to the mode of action, genital infections are the main problem. Extremely rare cases of ketoacidosis are reported, mostly in patients with Type 1 diabetes. One SGLT-2i, empagliflozin, has been shown to reduce cardiovascular mortality and progression of kidney disease in patients with Type 2 diabetes and cardiovascular disease. Outcome trials for other SGLT-2i are pending. SGLT-2i are now in guidelines as a possible second-line therapy or in case of metformin intolerance.
AB - The sodium-glucose cotransporter 2 inhibitor (SGLT-2i)-class is efficacious as monotherapy and as add-on therapy with an expected lowering of the glycated haemoglobin (HbA1c) concentration of approximately 7 mmol/mol. Side effects relate to the mode of action, genital infections are the main problem. Extremely rare cases of ketoacidosis are reported, mostly in patients with Type 1 diabetes. One SGLT-2i, empagliflozin, has been shown to reduce cardiovascular mortality and progression of kidney disease in patients with Type 2 diabetes and cardiovascular disease. Outcome trials for other SGLT-2i are pending. SGLT-2i are now in guidelines as a possible second-line therapy or in case of metformin intolerance.
KW - English Abstract
KW - Journal Article
M3 - Tidsskriftartikel
C2 - 27649712
VL - 178
SP - 2461
EP - 2464
JO - Ugeskrift for Laeger
JF - Ugeskrift for Laeger
SN - 0041-5782
IS - 26
M1 - V05160310
ER -
ID: 181027142